Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
A malignant fibrous histiocytoma is a type of cancerous tumor that can start in either bone or, most often, in the soft tissues that connect, support or surround organs and other body parts.Dana-Farber/Boston Children’s Cancer and Blood Disorders Center provides comprehensive medical and surgical care for children and adolescents with benign or malignant bone and soft tissue tumors.
How Dana-Farber/Boston Children’s Cancer and Blood Disorders Center approaches malignant fibrous histiocytoma
Our multidisciplinary approach to care ensures in-depth discussion of each case and personalized treatment plans for every patient. We integrate expertise from the following specialists at Dana-Farber Cancer Institute and Boston Children’s Hospital.
We are conducting numerous research studies to help better understand and treat soft tissue and bone sarcomas.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”